Recent discussions on X about Tempus AI, Inc. (TEM) have been ignited by the company's latest FDA 510(k) clearance for its RNA-based xR IVD device and updates to its AI-driven diagnostic platforms. Many users are pointing to this regulatory milestone as a potential catalyst for future growth, especially in the realm of precision medicine and oncology. The buzz around these advancements has kept the stock in the spotlight, with significant attention on its soaring share price.
Additionally, there’s considerable chatter about the stock’s technical performance and strong revenue growth, with some on X noting breakout patterns and high short interest as factors driving momentum. Comments also highlight the intersection of AI and healthcare as a hot theme, fueling excitement around the company’s long-term prospects. Despite some mentions of short-seller pressure, the overall tone leans toward optimism for Tempus AI’s trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 104 times in the past 6 months. Of those trades, 0 have been purchases and 104 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 44 sales selling 1,365,460 shares for an estimated $97,784,895.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 20 sales selling 85,280 shares for an estimated $5,610,400.
- THEODORE LEONSIS has made 0 purchases and 3 sales selling 64,770 shares for an estimated $4,643,220.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 8 sales selling 63,396 shares for an estimated $4,529,084.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 9 sales selling 30,649 shares for an estimated $2,024,803.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 9 sales selling 24,373 shares for an estimated $1,619,008.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 5 sales selling 7,977 shares for an estimated $526,163.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,240 shares for an estimated $72,414.
- JENNIFER A DOUDNA has made 0 purchases and 2 sales selling 1,183 shares for an estimated $69,876.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Government Contracts
We have seen $18,460,020 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 09/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- BTIG issued a "Buy" rating on 08/20/2025
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
- Needham issued a "Buy" rating on 05/07/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 7 analysts offer price targets for $TEM in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Subbu Nambi from Guggenheim set a target price of $95.0 on 09/26/2025
- Yi Chen from HC Wainwright & Co. set a target price of $98.0 on 09/12/2025
- Mark Massaro from BTIG set a target price of $85.0 on 08/20/2025
- Tejas Savant from Morgan Stanley set a target price of $68.0 on 08/12/2025
- Michael Ryskin from B of A Securities set a target price of $70.0 on 06/25/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 05/15/2025
- Ryan MacDonald from Needham set a target price of $70.0 on 05/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
